Wellbutrin
Binge Eating Disorder
Yale UniversityPhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Binge Eating Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Namenda Mclean Hospital | Phase 4 | BB |
Armodafinil Lindner Center of HOPE | Phase 3 | BB |
LAMOTRIGINE Lindner Center of HOPE | Phase 3 | BB |
Ctc-501 Neuropsychiatric Research Institute, Fargo, North Dakota | Phase 3 | B |
Naltrexone Yale University | Phase 2/3 | B |
Phentermine Lindner Center of HOPE | Phase 2 | B |
Tirzepatide Johns Hopkins University | Phase 2 | CCC |
GLUCAGON-LIKE PEPTIDE 1, HUMAN Haukeland University Hospital | D |
Same molecule, other indications
Wellbutrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →